{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=44", "query": { "condition": "Immune Dysfunction", "page": 44 }, "page_size": 10 }, "pagination": { "page": 44, "page_size": 10, "total_count": 20607, "total_pages": 2061, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=45&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=43&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T17:39:05.377Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02500706", "title": "Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Faster-acting insulin aspart", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" }, { "name": "insulin degludec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1108, "start_date": "2016-05-04", "completion_date": "2017-08-16", "has_results": true, "last_update_posted_date": "2019-06-12", "last_synced_at": "2026-10-21T17:39:05.377Z", "location_count": 57, "location_summary": "Tucson, Arizona • Concord, California • Encino, California + 49 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500706" }, { "nct_id": "NCT01777152", "title": "ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaplastic Large-Cell Lymphoma", "Non-Hodgkin Lymphoma", "T-Cell Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 452, "start_date": "2013-01-31", "completion_date": "2020-10-02", "has_results": true, "last_update_posted_date": "2021-11-30", "last_synced_at": "2026-10-21T17:39:05.377Z", "location_count": 32, "location_summary": "Gilbert, Arizona • Duarte, California • Stanford, California + 24 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01777152" }, { "nct_id": "NCT01752855", "title": "Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "New formulation adalimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2012-12", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2014-10-29", "last_synced_at": "2026-10-21T17:39:05.377Z", "location_count": 6, "location_summary": "Mesa, Arizona • Hemet, California • Wichita, Kansas + 3 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Hemet", "state": "California" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Clifton", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01752855" }, { "nct_id": "NCT06171685", "title": "MMRC Horizon One: RRMM (MMRC-099)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapse Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Teclistamab Monotherapy", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Multiple Myeloma Research Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 300, "start_date": "2024-11-17", "completion_date": "2030-07-31", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-21T17:39:05.377Z", "location_count": 13, "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06171685" }, { "nct_id": "NCT02756208", "title": "A Safety and Immunogenicity Trial of IHV01", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "300 ug FLSC vaccine", "type": "BIOLOGICAL" }, { "name": "150 ug FLSC vaccine", "type": "BIOLOGICAL" }, { "name": "75 ug FLSC vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 65, "start_date": "2015-11", "completion_date": "2018-07", "has_results": true, "last_update_posted_date": "2021-12-16", "last_synced_at": "2026-10-21T17:39:05.377Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02756208" }, { "nct_id": "NCT00925925", "title": "Epigenetic Markers of B-Cell Function in Low Birth Weight Infants", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Low Birth Weight", "Small for Gestational Age", "Immunodeficiency" ], "interventions": [ { "name": "Cord blood collection for analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "2 Hours", "sex": "ALL", "summary": "Up to 2 Hours" }, "enrollment_count": 64, "start_date": "2009-06", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2015-05-12", "last_synced_at": "2026-10-21T17:39:05.377Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00925925" }, { "nct_id": "NCT04134325", "title": "Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Relapsed Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-09-01", "completion_date": "2037-07-07", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-21T17:39:05.377Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04134325" }, { "nct_id": "NCT04981925", "title": "Predictors of Pain Relief From Mindfulness-based Stress Reduction (MBSR) in Multiple Forms of Chronic Pain Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Pain Syndrome" ], "interventions": [ { "name": "MBSR treatment", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 381, "start_date": "2021-08-01", "completion_date": "2025-02-27", "has_results": false, "last_update_posted_date": "2025-08-24", "last_synced_at": "2026-10-21T17:39:05.377Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04981925" }, { "nct_id": "NCT00030589", "title": "Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "bexarotene", "type": "DRUG" }, { "name": "methoxsalen", "type": "DRUG" }, { "name": "UV light therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Millennix", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-10-21T17:39:05.377Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030589" }, { "nct_id": "NCT02519452", "title": "A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab Subcutaneous (SC) Administration", "type": "DRUG" }, { "name": "Recombinant Human Hyaluronidase [rHuPH20]) SC Administration", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2015-10-22", "completion_date": "2023-04-03", "has_results": false, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-10-21T17:39:05.377Z", "location_count": 4, "location_summary": "Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02519452" } ] }